Equities Analysts Offer Predictions for CLDX FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Celldex to a loss of $4.05 per share from a projected loss of $4.23, and reiterated its Buy rating with a $64 price target.
• Celldex reported a quarterly loss of $0.96 per share, beating analysts’ $1.02 loss estimate, while revenue of $0.40 million came in below the $0.72 million forecast.
• Analyst sentiment is mostly positive: 11 of 13 analysts rate the stock Buy, with an average rating of “Moderate Buy” and a consensus price target of $64.08.

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Celldex Therapeutics in a report issued on Friday, November 6th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of ($4.05) for the year, up from their previous forecast of ($4.23). HC Wainwright currently has a "Buy" rating and a $64.00 target price on the stock. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($4.17) per share. HC Wainwright also issued estimates for Celldex Therapeutics' Q4 2026 earnings at ($0.99) EPS and FY2027 earnings at ($4.28) EPS.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.06. The company had revenue of $0.40 million during the quarter, compared to analysts' expectations of $0.72 million.

CLDX has been the topic of a number of other reports. Canaccord Genuity Group boosted their target price on shares of Celldex Therapeutics from $60.00 to $68.00 and gave the company a "buy" rating in a research note on Monday. Morgan Stanley raised their price target on shares of Celldex Therapeutics from $57.00 to $61.00 and gave the stock an "overweight" rating in a research note on Monday. Wells Fargo & Company lifted their price target on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Leerink Partners upped their price objective on Celldex Therapeutics from $70.00 to $88.00 and gave the company an "outperform" rating in a research note on Wednesday, September 23rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Celldex Therapeutics in a report on Thursday, October 15th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $64.08.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $31.24 on Tuesday. Celldex Therapeutics has a 52-week low of $22.10 and a 52-week high of $45.14. The company has a 50-day simple moving average of $32.77 and a 200 day simple moving average of $32.70. The company has a market capitalization of $2.45 billion, a PE ratio of -7.27 and a beta of 1.04.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLDX. Diversified Trust Co boosted its position in Celldex Therapeutics by 2.9% during the third quarter. Diversified Trust Co now owns 32,239 shares of the biopharmaceutical company's stock worth $1,045,000 after purchasing an additional 909 shares during the period. Fisher Asset Management LLC increased its stake in shares of Celldex Therapeutics by 26.5% in the third quarter. Fisher Asset Management LLC now owns 1,246,855 shares of the biopharmaceutical company's stock worth $40,411,000 after purchasing an additional 261,178 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Celldex Therapeutics by 11.0% in the third quarter. Russell Investments Group Ltd. now owns 111,489 shares of the biopharmaceutical company's stock worth $3,613,000 after purchasing an additional 11,037 shares in the last quarter. Three Bridge Wealth Advisors LLC bought a new stake in shares of Celldex Therapeutics in the third quarter valued at approximately $40,000. Finally, Candriam S.C.A. raised its position in shares of Celldex Therapeutics by 7.8% in the third quarter. Candriam S.C.A. now owns 518,476 shares of the biopharmaceutical company's stock valued at $16,865,000 after purchasing an additional 37,351 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells.

The company's lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity.

Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.